{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.591","upperLimit":"0.99","value":"0.929"},{"groupId":"OG001","lowerLimit":"0.239","upperLimit":"0.246","value":"0.240"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"* 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.\n* Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).\n* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.\n\nBKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.\n\nCisplatin: Cisplatin is a chemotherapy drug\n\nIntensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells","id":"OG000","title":"Dose Level 1"},{"description":"* 40 mg BKM120 will be administered orally daily for 45 days.\n* Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).\n* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.\n\nBKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.\n\nCisplatin: Cisplatin is a chemotherapy drug\n\nIntensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells","id":"OG001","title":"Dose Level 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"24 Month Overall Survival","type":"SECONDARY","unitOfMeasure":"probability of survival"}